News | December 26, 2023
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Additionally, Rs. 12.85 crores shall be infused into the P H Diagnostic by way of either Equity or Loan to pay the existing debt
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Both the India and GCC entities will be operated by separate dedicated management teams
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Total transaction value of the divestment is Rs. 3,660 million
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Subscribe To Our Newsletter & Stay Updated
